ProCE Banner Activity

ExpressPoints
Treating EGFR Exon 20 Insertion+ mNSCLC: Equipping Oncology Nurses to Optimize Care

Slideset Download
Gain clinical insights fast, with this short summary slideset of key takeaways from a live symposium at ONS 2022 on how experts approach management of patients with EGFR ex20ins+ advanced NSCLC.

Released: May 11, 2022

Expiration: May 10, 2023

No longer available for credit.

Share

Faculty

Marianne Davies

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Takeda Pharm USA

Faculty Disclosure

Primary Author

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Professor
Coordinator of Oncology Concentration

Yale University School of Nursing
Oncology Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP, FAAN, has no conflicts of interest to report.

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genzyme/Sanofi, iTeos, and Surface and funds for research support to his institution from Amgen, Johnson & Johnson, Merck, Novartis, OncoMed, Roche, and Trizell.